LB Pharmaceuticals Inc.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Stock Performance (90 Days)
Layoff History
Recent News
Other Biotechnology Companies
View All →Frequently Asked Questions
Has LB PHARMACEUTICALS INC had layoffs?
How many employees does LB PHARMACEUTICALS INC have?
What industry is LB PHARMACEUTICALS INC in?
Is LB PHARMACEUTICALS INC a publicly traded company?
Where is LB PHARMACEUTICALS INC headquartered?
Disclaimer
Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.
This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.
Found an error? Report it here.